智通财经APP获悉，美国卫生与公共服务部部长肯尼迪周三表示，美国食品药品监督管理局(FDA)已撤 销此前实施的新冠疫苗紧急使用授权，并对辉瑞(PFE.US)的疫苗接种对象设置了更严格的限制。 肯尼迪在社交媒体平台X上写道："新冠疫苗的紧急使用授权，这一在拜登政府期间被用来为全民接种 强制令提供依据的措施，现已被撤销。" 根据新规，Moderna(MRNA.US)的新冠疫苗仍可供6个月及以上儿童接种，而辉瑞的疫苗则被限制在5岁 及以上人群。至于诺瓦瓦克斯(PFE.US)，其疫苗仅限12岁及以上人群使用。相比拜登政府时期推荐所有 6个月以上美国人每年接种一次的政策，此次调整显得明显收紧。 肯尼迪强调："美国人民要求科学、安全与常识，而这一框架同时满足了三者。"不过，FDA尚未就此发 布正式公告。 与此同时，FDA周三批准了辉瑞公司针对新冠疫苗的补充生物制品许可申请，其品牌名称为 Comirnaty。此次批准针对65岁及以上人群，以及5至64岁之间患有至少一种基础疾病、且存在新冠重症 风险的群体。 目前仍存在悬而未决的问题，包括对于无基础疾病的健康人群，疫苗是否仍可获得，以及保险公司是否 会继续为相关人群承担费用。 ...

Group 1: Intuitive Surgical - Intuitive Surgical is a leader in robotic-assisted surgery (RAS) devices, primarily driven by its da Vinci system, which allows for minimally invasive surgeries across various medical fields [4] - The company has faced challenges such as a decline in bariatric surgeries and tariffs, but its long-term prospects remain strong due to a resilient business model and consistent growth in revenue [5][9] - The addressable market for Intuitive Surgical is underpenetrated, with over half of its revenue coming from instruments and accessories tied to procedure volume, benefiting from an aging global population [7][8] - Intuitive Surgical has outperformed the market for 25 years, indicating potential for significant capital growth for younger investors [9] Group 2: Moderna - Moderna is considered a riskier investment compared to Intuitive Surgical but has substantial upside potential, particularly due to its successful COVID-19 vaccine and innovative mRNA platform [10] - The company has achieved several clinical and regulatory successes, including approvals for vaccines against RSV and ongoing trials for vaccines targeting influenza and cancer [11][13] - Despite a recent lag in stock performance due to declining sales from its coronavirus vaccine franchise, Moderna's pipeline remains promising, with potential candidates for various cancers and an early-stage HIV vaccine [12][14] - If Moderna successfully mainstreams mRNA vaccines over the next five years, it could lead to significant stock upside, making it a consideration for younger investors who can tolerate volatility [14]

Core Viewpoint - Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, potentially leading to supply shortages, with Moderna stepping in to fill gaps [1][2][3] Group 1: FDA Authorization and Vaccine Availability - The FDA may not renew the emergency use authorization for Pfizer's pediatric COVID-19 vaccine for the 2025 respiratory season, which could remove the only vaccine available for children under five [2][3] - Pfizer anticipates full FDA approval for its COVID-19 vaccine for children aged 5 to 11 this fall, but options for the youngest age group would be limited without authorization [3] Group 2: Current Vaccine Landscape - Moderna's pediatric vaccine, approved in July, is only available for children with specific health conditions, while Novavax's pediatric shot is available for children 12 and older with similar conditions [4] - The CDC is in discussions with Moderna to increase vaccine supply for young children in anticipation of potential gaps [4] Group 3: Vaccination Rates and Public Health Concerns - Health experts express concern that narrowing vaccine access could further decrease already low vaccination rates, with only 5.6% of children aged six months to four years vaccinated and 15% of children aged 5 to 17 [5] - Despite low uptake, the vaccines are noted to be highly effective in preventing hospitalization and death [5] Group 4: Regulatory Changes and Controversies - The U.S. Health and Human Services Secretary announced that the COVID-19 vaccine will no longer be recommended for pregnant women and healthy children on the CDC's immunization schedule [6] - The FDA has implemented stricter clinical trial requirements for healthy adults and limited annual booster approvals to older and high-risk Americans [7] - A lawsuit has been filed against Robert F. Kennedy Jr. for changes to COVID-19 vaccine recommendations, which plaintiffs argue undermine science and public health [8]

Core Viewpoint - The global pharmaceutical industry is experiencing a downturn in the capital market due to uncertain policies from the Trump administration, leading to increased cost pressures and a trend of cost-cutting measures among major companies [2][3]. Market Performance - The S&P 500 healthcare sector index has declined by approximately 5% this year, while the overall S&P 500 index has increased by over 7% [2]. - The price-to-earnings (P/E) ratio for the healthcare sector has dropped from nearly 20 times to about 16 times over the past year [3]. Company Actions - Merck has announced a cost-cutting and layoff plan aimed at saving $3 billion annually by 2027, with an expected cost increase of $200 million due to tariffs [3]. - Pfizer has initiated a significant cost reduction plan, targeting net savings of approximately $4.5 billion by the end of 2025 and $7.2 billion by the end of 2027 [4]. - Moderna is facing financial challenges, with its stock price down over 75% in the past year, and plans to cut its workforce by 10% [5]. Future Growth Strategies - Companies are focusing on advancing their drug pipelines to drive future growth, with Novo Nordisk highlighting ongoing clinical trials for key products [6]. - The pharmaceutical industry is facing a wave of patent expirations in the coming years, with nearly $200 billion in sales from drugs set to lose patent protection before 2030 [7]. Mergers and Acquisitions - There has been a notable decrease in large-scale acquisitions in the pharmaceutical sector, with companies now favoring smaller deals to achieve higher returns [8]. - Chinese companies are increasingly attracting interest from global pharmaceutical firms, with licensing deals valued at $35 billion in the first half of the year [9].

在美国特朗普政府不确定的政策影响下，今年全球制药行业在资本市场的表现低迷，关税及药品价格下 调等因素导致企业成本压力上升。在近期公布的第二季度财报中，多家制药企业宣布削减成本，并将采 取减员计划。 今年至今，总市值近5万亿美元规模的标普500医疗保健板块指数下跌约5%，同期标普500指数涨幅超过 7%，美国市场医疗股资金净流出规模也超过其他任何行业。 医疗板块资本市场遇冷 根据伦敦证券交易所数据流（LSEG Datastream）的最新数据，基于对未来一年盈利预测，医疗保健行 业市盈率已从一年前的近20倍降至约16倍。默沙东及百时美施贵宝（BMS）的预期市盈率分别仅为8.7 倍和7.4倍，低于行业平均水平。两家公司今年以来股价累计跌幅都接近20%。 在最新季度的财报中，尽管大部分制药企业都上调了年度利润预期，但由于关税及药品价格谈判等不确 定性因素导致的成本上升风险依然存在。在这一背景下，包括默沙东、辉瑞、诺和诺德在内的制药巨头 都表示将进一步采取行动削减成本。 默沙东已经宣布了一项成本削减和减员计划，预计在2027年前，每年节省30亿美元开支。公司表示，基 于目前关税的水平，相应成本增加预计达到2亿美元。而 ...

每经记者｜宋欣悦 每经编辑｜陈柯名 兰素英 ④ 【AMD二季度"增收不增利"，盘前跌超5%】美芯片巨头AMD盘前跌超5%。消息面上，公司最新公布的财报显示，其二季度的营收超出预期，不过， 二季度营业利润率仅为12%，上年同期为22%。二季度调整后净利润7.81亿美元，同比下降31%。 ⑤ 【马斯克：特斯拉正在训练新的FSD模型】8月6日，马斯克在X上发文称，特斯拉正在训练新的FSD模型，新模型的参数规模约为当前版本的十倍，如 果一切顺利则可能会在下个月底准备好面向公众发布。 ⑥ 【大幅下调营收指引，超微电脑盘前跌超16%】超微电脑盘前跌超16%。消息面上，超微电脑公布的第四财季报告显示，公司预计下季度营收在60亿 ~70亿美元之间，调整后每股收益在0.40~0.52美元之间。2026财年营收预期从此前的400亿美元下调至330亿美元，降幅达17.5%。 ⑦ 【诺和诺德减肥药Wegovy第二季度销售额飙升67%】周三，丹麦制药巨头诺和诺德公布了其2025年第二季度财报。财报显示，其核心产品Wegovy二季 度销售额同比大增67%，至195.3亿丹麦克朗。 ⑧ 【美国卫生部撤回mRNA疫苗开发拨款，众多疫苗大厂" ...

Core Viewpoint - The U.S. government has decided to cancel approximately $500 million in funding for mRNA vaccine development, marking a significant shift away from mRNA technology in public health strategy [2][3]. Group 1: Decision Details - U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced the cancellation of the mRNA vaccine development project, which includes the termination of 22 contracts related to mRNA technology by the Biomedical Advanced Research and Development Authority (BARDA) [2][3]. - The decision is influenced by consultations with top experts from the National Institutes of Health (NIH) and the FDA, concluding that the risks of mRNA technology outweigh its benefits for respiratory viruses like COVID-19 and influenza [3][4]. - The U.S. Department of Health and Human Services plans to redirect the canceled funds to "safer and broader vaccine platforms" that remain effective even with viral mutations [3]. Group 2: Expert Opinions - Many experts argue that mRNA vaccines have a significant advantage in rapid development and adaptability, which is crucial for responding to emerging viruses and variants [6]. - Dr. Peter Hotez criticized the decision as undermining national biosecurity and promoting a "pseudo-scientific agenda" [6]. - Dr. Paul Offit expressed concern that the decision was made without scientific evidence, potentially exposing the nation to unnecessary risks [6]. Group 3: Industry Impact - The cancellation of contracts with companies like Moderna and others indicates a broader shift in the U.S. government's approach to vaccine development, which may affect future innovations in the biomedical field [5][6]. - The U.S. Department of Health and Human Services is also terminating contracts with Emory University and Tiba Biotech, which were working on mRNA-based antiviral platforms [6].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, and has compiled detailed reports on more than 1,000 companies [1]

Group 1: Market Performance - Dongyue Group (00189) saw a rise of over 1%, with expectations for increased refrigerant demand as the new cooling season begins, despite a seasonal decline in August [1] - Hong Kong's banking stocks experienced a rally, with Agricultural Bank (01288) up over 2%, and other banks like ICBC (01398) and China Merchants Bank (03968) also gaining over 1%. The overall asset quality of listed banks remains stable, and profit growth is expected to continue [1] - In the gold sector, Lingbao Gold (03330) rose over 3%, with other companies like Chifeng Jilong Gold (06693) and Shandong Gold (01787) also seeing significant gains, driven by lower-than-expected U.S. job growth data which increased interest in gold [3] Group 2: Company Announcements - InnoCare (02577) surged over 8% after being named the only Chinese chip company in NVIDIA's 800VDC power architecture collaboration, indicating a significant partnership in AI data centers [2] - Derun Shipping (02510) announced a profit forecast of approximately $180 million to $200 million for the six months ending June 30, 2025, representing a 220% to 255% increase compared to the previous year [2] - China Eastern Education (00667) reported an expected profit increase of no less than 45% for the first half of the year, driven by a 7% increase in new student registrations and effective cost control [3] Group 3: Financial Results - Amazon (AMZN.US) reported second-quarter earnings that exceeded expectations, with AWS revenue growing 17% year-over-year, but the third-quarter profit guidance fell short of market expectations [5] - Coinbase (COIN.US) saw a 16.7% drop after reporting second-quarter revenue of $1.5 billion, which was below analyst expectations, despite a significant profit increase due to investments [5] - Moderna (MRNA.US) experienced a decline of over 10% due to delays in vaccine shipments, leading to a downward revision of its revenue forecast for 2025 [7]

Core Insights - Moderna announced a global workforce reduction of approximately 10%, which translates to nearly 800 employees, bringing the total number of employees below 5,000 by the end of the year [1][3] - The decision to cut jobs is driven by a significant decline in vaccine sales revenue, with the company's stock price dropping over 75% in the past year and market capitalization plummeting from nearly $200 billion to around $11 billion, a decrease of over 90% [3] Financial Pressure and Strategic Adjustments - To address the revenue decline, Moderna has implemented several cost-cutting measures, including a plan to reduce annual operating expenses by approximately $1.5 billion by 2027 [3] - The company also canceled plans to build an mRNA drug manufacturing facility in Japan due to changes in the global and Japanese business environment, indicating a strategic retreat from non-core business investments [3] Market Environment Challenges - Changes in U.S. health policy have directly impacted Moderna's business, including the withdrawal of long-term vaccination recommendations for children and pregnant women, which has narrowed the market for its latest vaccine [4] - The termination of a contract for developing an avian flu vaccine further constricts the company's business scope [4] - Moderna's second major product, the respiratory syncytial virus vaccine, has not gained significant market attention, leading to a downward revision of the company's revenue expectations for the year [4] - The timeline for achieving breakeven has been pushed from 2026 to 2028 due to underperformance in sales [4] - Despite these challenges, the CEO remains optimistic, highlighting that Moderna currently has three approved products and up to eight more expected to be approved within the next three years [4]